Evidence map›Paper›PMID 35379687›Full record

ArticleBJGP open2022

Multicentre oncology clinical trials in primary health care in Cuba: evaluation of programme implementation in Villa Clara Province, 2010-2020.

Geidy Lorenzo, Ramón Alberto Ortiz, Rayza Méndez, Migdalia Rodríguez, Rayza Marrero, Nieves Del Carmen de la Barca, María Cecilia Granela, Maritza Artiles, Menelio Norvel, Meylan Cepeda and 8 more

Abstract read
In one paragraph

Article in BJGP open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Geidy LorenzoCenter of Molecular Immunology, Havana, Cuba geydi@cim.sld.cu.ORCID https://orcid.org/0000-0002-5959-5665
Ramón Alberto Ortiz"Celestino Hernández Robau" Hospital, Villa Clara, Cuba.
Rayza MéndezNational Coordinating Centre of Clinical Trials, Villa Clara, Cuba.
Migdalia RodríguezNational Coordinating Centre of Clinical Trials, Villa Clara, Cuba.
Rayza MarreroNational Coordinating Centre of Clinical Trials, Villa Clara, Cuba.
Nieves Del Carmen de la BarcaChiqui Gómez Polyclinic, Vila Clara, Cuba.
María Cecilia GranelaRoberto Fleites Polyclinic, Villa Clara, Cuba.
Maritza ArtilesXX Aniversario Polyclinic, Villa Clara, Cuba.
Menelio NorvelMarta Abreu Polyclinic, Villa Clara, Cuba.
Meylan CepedaCenter of Molecular Immunology, Havana, Cuba.
Elsa ToledoCelestino Hernández Hospital, Villa Clara, Cuba.
Alexis GonzálezCelestino Hernández Hospital, Villa Clara, Cuba.
Juan Carlos CrespoCelestino Hernández Hospital, Villa Clara, Cuba.
Olga TorresCenter of Molecular Immunology, Havana, Cuba.
Leisy NietoCentral University of Las Villas, Villa Clara, Cuba.
Tania CrombetCenter of Molecular Immunology, Havana, Cuba.
Liset SánchezCenter of Molecular Immunology, Havana, Cuba.
Agustín LageCenter of Molecular Immunology, Havana, Cuba.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Center of Molecular Immunology of Cuba has developed a programme for the conducting of multicentre oncology clinical trials in primary healthcare centres since 2009.

aimTo evaluate the ability to conduct oncology clinical trials in primary health care. DESIGN &

settingA longitudinal, prospective, analytical study was developed between July 2010 and August 2020 in the Villa Clara province.

methodStructure, process, and outcome indicators were evaluated by the methods of a structured interview, direct observation, documentary observation, and databases analysis. The investigators' curricula vitae, the investigator site file, minutes of workshops, the monitoring reports, the clinical trial training records, and databases were employed as sources of information. The following criteria were considered adequate: when the indicator met the standard; and not adequate: when the indicator did not meet the standard.

resultsThe six structure indicators reached adequate results and showed that the programme has allowed building of capacities to conduct clinical trials in primary care. The eight processes indicators and two outcome indicators were considered adequate too. Trials conducted in primary care showed better indicators of patient recruitment than secondary care. Both scenarios showed similar behaviour for the process indicators: retention, protocol compliance, and safety. Survival and satisfaction with health services were also comparable in both scenarios.

conclusionThe evaluation of the programme showed adequate indicators for conducting oncology clinical trials in primary care in Villa Clara and these were comparable to those determined in the secondary care.

Indexed as

clinical trialsgeneral practitionersimmunotherapyneoplasmsoncologyprimary health careprimary healthcare

Identifiers

PMID35379687
PMCPMC9680758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.